NCT04169256View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of HYR-PB21 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

July 30, 2020

Study Completion Date

July 30, 2020

Conditions
Acute Postoperative Pain
Interventions
DRUG

HYR-PB21

HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen

DRUG

Liposomal bupivacaine

Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen

OTHER

Normal Saline

Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

All Listed Sponsors
lead

Fruithy Medical Pty Ltd

INDUSTRY

NCT04169256 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of HYR-PB21 in Healthy Volunteers | Biotech Hunter | Biotech Hunter